GPCR
Structure Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$47.34
+0.00%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.6x
Market Cap
$3.38B
MomentumView details →
1D Return
+0.00%
YTD Return
−31.95%
RSI (14)
41.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.6x
Market Cap
$3.38B
RSI (14)
41.6
MomentumView details →
1D Return
+0.00%
YTD Return
−31.95%
SummaryUpdated Jun 1, 2026
Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in South San Francisco, California. The company was formerly known as ShouTi Inc. before rebranding and went public in February 2023. Structure Therapeutics focuses on developing novel oral small molecule therapeutics targeting G-protein-coupled receptors (GPCRs) to treat chronic diseases with significant unmet medical needs, particularly in diabetes, obesity, and pulmonary diseases.
Similar companies
Latest newsMore news →
Structure Therapeutics is advancing its oral GLP-1 candidate aleniglipron into Phase 3 studies, with pivotal data expected in Q4 2028.14d agoStructure Therapeutics Inc. reported a net loss of $106.2 million for Q2 2026, with research and development expenses of $100.1 million and general and administrative expenses of $18.6 million.30d ago